Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis healing and maintenance
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Duodenal and gastric ulcers (healing)
* *Helicobacter pylori* eradication (in combination therapy)
### Adult Dosing
* **GERD and Erosive Esophagitis (Healing):** 20 mg to 40 mg once daily.
* **Erosive Esophagitis (Maintenance):** 20 mg once daily.
* **Pathological Hypersecretory Conditions:** Starting dose typically 40 mg twice daily; may increase to 80 mg twice daily. Doses >80 mg/day require further division.
* ***H. pylori* Eradication:** 40 mg twice daily for 7-14 days as part of a triple or quadruple therapy regimen.
### Pediatric Dosing
* **GERD (12 years and older):** 20 mg to 40 mg once daily.
* **GERD (less than 12 years):** Dosing varies significantly by indication and weight. Consult specific pediatric guidelines.
* For erosive esophagitis, doses typically range from 0.7 mg/kg to 1.3 mg/kg per day, not to exceed 40 mg per day.
### Dose Adjustments
No dose adjustment is typically needed for hepatic impairment, though caution is advised. No dose adjustment is necessary for renal impairment.
### Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence.
Less common: Dizziness, fatigue, rash, dry mouth, elevated liver enzymes.
Long-term PPI use may be associated with:
* Increased risk of *Clostridium difficile*-associated diarrhea
* Bone fractures (hip, wrist, spine)
* Hypomagnesemia
* Vitamin B12 deficiency
### Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, certain HIV protease inhibitors (e.g., atazanavir, nelfinavir), and mycophenolate mofetil. Separate administration by several hours if possible.
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider dose reduction or interruption of PPI.
* **CYP2C19 substrates/inhibitors:** Pantoprazole is a moderate inhibitor of CYP2C19.
### Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider magnesium levels in patients on long-term therapy, especially if taking other medications that can lower magnesium.
* Monitor bone mineral density in patients at risk for osteoporosis.
* For *H. pylori* eradication, confirm eradication post-treatment.
### Clinical Pearls
* Administer 30-60 minutes before a meal for optimal efficacy.
* Pantoprazole delayed-release tablets and granules are enteric-coated and should not be crushed or chewed. They can be mixed with applesauce or apple juice.
* Intravenous formulation is available for patients unable to take oral medications.
* Long-term use should be reserved for patients with a clear indication and periodically reassessed.
***
**Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information, including dosing, contraindications, and warnings, with the most recent official drug monograph or product labeling, as well as consult local institutional protocols.
